SWOG-9023, DNA Analysis of Tumor Tissue From Patients With Metastatic Kidney Cancer

SWOG Cancer Research Network

Status: Completed

Conditions: Kidney Cancer

Treatments: Genetic: DNA ploidy analysis; Other: flow cytometry; Genetic: chromosomal translocation analysis; Other: laboratory biomarker analysis; Genetic: DNA stability analysis; Genetic: cytogenetic analysis

Study type: Observational

Funder types: NETWORK; NIH

Identifiers

NCT00900042

CDR0000502305

SWOG-9023 (Other Identifier)

U10CA032102 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

RATIONALE: DNA analysis of tumor tissue may help doctors predict how well patients will respond to treatment.

PURPOSE: This laboratory study is analyzing the DNA in tumor tissue from patients with metastatic kidney cancer.

Full description

OBJECTIVES:

• Determine if cytogenetic abnormalities can predict clinical outcome, in terms of response to treatment and survival, in patients with metastatic renal cell carcinoma registered to the nephrectomy arm (arm I) of SWOG-8949.
• Correlate cytogenetic abnormalities and DNA content analysis (DNA index and S-phase fraction) with clinical outcome.

OUTLINE: This is a partially prospective, partially retrospective, multicenter, companion study.

Paraffin-embedded tumor tissue specimens from patients enrolled in SWOG-8949 are evaluated by cytogenetic analysis (e.g., presence of trisomy and loss of Y chromosome) and flow cytometric analysis (e.g., presence of nondiploid cells and presence of abnormal proliferation index).

PROJECTED ACCRUAL: A total of 80 patients will be accrued for this study.

Enrollment: 34 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

• Diagnosis of renal cell carcinoma

  • Any T, any N, M1 disease as specified in SWOG-8949

• Eligible for and registered on the nephrectomy arm* (arm I) of SWOG-8949 NOTE: *Patients must be registered on this study before undergoing nephrectomy on SWOG-8949

PATIENT CHARACTERISTICS:

• Not specified

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics